Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Survivin DC cell injection for newly diagnosed GBM
NCT06524063Phase 1Not yet recruiting
- Sponsor
- Tricision Biotherapeutics
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label, single-arm trial of PERCELLVAC-Sur in glioblastoma (GBM), sponsored by Tricision Biotherapeutics. Primary endpoint: Dose Limiting Toxicity at 28 days. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
PERCELLVAC-Sur
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06524063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524063.